title: Enhanced resistance against lethal disseminated Candida albicans infection in mice treated with polar glycopeptidolipids from Mycobacterium chelonae (pGPL-Mc).
abstract: Intraperitoneal administration of polar glycopeptidolipids extracted from Mycobacterium chelonae (pGPL-Mc) greatly increased the resistance of mice against a lethal disseminated Candida albicans infection. This enhanced resistance was demonstrated by an increase in the number of survivors and the prolongation of the mean survival time of animals following a lethal challenge. These effects were dependent upon the infective dose of Candida albicans, the dose of pGPL-Mc and the timing of its administration. This enhanced resistance was correlated with the development and persistence of a hyperleukocytosis, associated with a long lasting increase in the number of polymorphonuclear neutrophils. On the contrary, no candidacidal effect of the serum collected from pretreated mice was observed; suggesting that the ability of pGPL-Mc to increase resistance against Candida albicans infection is likely to be mediated by polymorphonuclear neutrophils. These results confirm previously described immunostimulating properties of pGPL-Mc and open the way for the evaluation of its effect in the prevention of opportunistic infections in neutropenic patients.
authors.affiliation: Service de microbiologie, Hôpital Saint-Louis, Paris, France.
authors.forename: P H
authors.initials: PH
authors.lastname: Lagrange
authors.forename: M
authors.initials: M
authors.lastname: Fourgeaud
authors.forename: T
authors.initials: T
authors.lastname: Neway
authors.forename: C
authors.initials: C
authors.lastname: Pilet
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002176:Candida albicans / Q000254:growth & development*; D002177:Candidiasis / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D005260:Female; D006017:Glycolipids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006020:Glycopeptides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007962:Leukocytes / Q000187:drug effects; D007964:Leukocytosis / Q000188:drug therapy; D051379:Mice; D016926:Mycobacterium chelonae / Q000737:chemistry*
chemical_list: D000276:Adjuvants, Immunologic; D006017:Glycolipids; D006020:Glycopeptides